Drug Profile
CRE 16257
Alternative Names: EML 16257; EML 257Latest Information Update: 15 May 2003
Price :
$50
*
At a glance
- Originator Merck KGaA; Ono Pharmaceutical
- Developer Merck KGaA; Merck Sante
- Class
- Mechanism of Action B cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Insulin resistance; Type 2 diabetes mellitus
Most Recent Events
- 15 May 2003 Discontinued - Phase-II for Insulin resistance in Europe (unspecified route)
- 15 May 2003 Discontinued - Phase-II for Type-2 diabetes mellitus in Europe (PO)
- 28 Feb 2003 Phase-II clinical trials in Insulin resistance in Europe (unspecified route)